ArticleHaematologica2017
The clinical and molecular diversity of mast cell leukemia with or without associated hematologic neoplasm.
Article in Haematologica, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 51 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
51 citing papers in PubMed, 95 citations in OpenAlex.
- Efficacy and safety of avapritinib in previously treated patients with advanced systemic mastocytosis.Blood advances · 2022Trial
- Efficacy and safety of midostaurin in patients with advanced systemic mastocytosis: 10-year median follow-up of a phase II trial.Leukemia · 2018Trial
- KIT mutation and AHN-associated oncogenic profiles in systemic mastocytosis with an associated hematological neoplasm.Blood advances · 2026Article
- Review
- Diagnosing Systemic Mastocytosis: State of the Art.International journal of laboratory hematology · 2026Review
- Impact of Molecular Evaluations in the Biology, Diagnosis, and Prognostication of Patients With Mastocytosis.The journal of allergy and clinical immunology. In practice · 2026Review
- Case Report: Experience of a rare case of primary acute mast cell leukemia with FGFR1 gene rearrangement.Frontiers in oncology · 2026Article
- Case report: A case of mast cell leukemia treated with avapritinib: from diagnostic challenge to transplantation.Frontiers in oncology · 2026Article
- Midostaurin in daily clinical practice of patients with advanced systemic mastocytosis.British journal of haematology · 2025Article
- Mast Cell Leukemia: Comprehensive Review of Literature With Current Insights and Updates on Management.Journal of hematology · 2025Review
- Mast cell leukemia: a rare case report and literature review.Frontiers in oncology · 2025Article
- Potential Off-Target Effect of Gilteritinib With Venetoclax Decreases Tumor Burden for Patients With Relapsed/Refractory Wild-TypeCase reports in hematology · 2025Article
- Treatment refractory mast cell leukemia with dominant gastrointestinal manifestation and concomitant skin symptoms: A case report.World journal of clinical cases · 2024Article
- Serum chemistry profiling and prognostication in systemic mastocytosis: a registry-based study of the ECNM and GREM.Blood advances · 2024Article
- Poor Applicability of Currently Available Prognostic Scoring Systems for Prediction of Outcome inCancers · 2024Article
- Mastocytosis demystified.Hematology. American Society of Hematology. Education Program · 2023Review
- Aleukemic Variant of Mast Cell Leukemia with del (7)(q31): Rare Case Report of an Elderly Chinese ManTurkish journal of haematology : official journal of Turkish Society of Haematology · 2023Article
- Response and resistance to cladribine in patients with advanced systemic mastocytosis: a registry-based analysis.Annals of hematology · 2023Article
- Mast cell leukemia: clinical and molecular features and survival outcomes of patients in the ECNM Registry.Blood advances · 2023Article
- Mast Cell Leukemia: An Update with a Practical Review.Cancers · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 9 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mast cell leukemia is a rare variant of advanced systemic mastocytosis characterized by at least 20% of mast cells in a bone marrow smear. We evaluated clinical and molecular characteristics of 28 patients with (n=20, 71%) or without an associated hematologic neoplasm.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.